End Stage Renal Disease Program

Dialysis Patient Citizens Responds to Disappointing Final CMS Rule That Will Harm Patient Healthcare

Retrieved on: 
Monday, October 30, 2023
Dialysis, DPC, ESRD, End Stage Renal Disease Program, Workforce, Patient, Kidney, Centers for Medicare & Medicaid Services, Biden administration COVID-19 action plan, CMS, Medicare, Multimedia, Itch, Health insurance

"The End Stage Renal Disease (ESRD) final rule released on Friday paints a chilling picture of an agency that is completely indifferent to the suffering of dialysis patients," said DPC President Andrew Conkling.

Key Points: 
  • "The End Stage Renal Disease (ESRD) final rule released on Friday paints a chilling picture of an agency that is completely indifferent to the suffering of dialysis patients," said DPC President Andrew Conkling.
  • "The rule also refuses to acknowledge the injustice of dialysis patients who experience pruritis (itching) being unable to obtain a new, effective treatment for this condition, due to the agency's inflexible dialysis payment methodology.
  • The rule further solidifies an outrageous status quo, perpetuating unnecessary suffering and deterring researchers and venture capitalists from pursuing improvements to kidney care.
  • CMS needs to do more than just acknowledge the plight of dialysis patients – it should take concrete steps to increase access to life-saving treatments."

Invitae to Present Data at the National Society of Genetic Counselors 42nd Annual Conference That Supports Advancements in Medical Genomics

Retrieved on: 
Tuesday, October 10, 2023
Steps, National Society of Genetic Counselors, NYSE, Classification, Sibling, Breast cancer, Health, Genetic counseling, CGC, Gene, Phenotype, Research, AGS, Conference, Fiat 500X, NSGC, DNA, DSM-IV codes, Boston Children's Hospital, MPH, KCNQ2, Aicardi–Goutières syndrome, ACMG, Prostate cancer, National Society, RNA, Effectiveness, Risk, Cancer, Heart, Population genomics, University of Connecticut Health Center, SAN, End Stage Renal Disease Program, Senior counsel, Huntington's disease, Uncertainty, Family, LCGC, Genetic, VUS, UPMC Children's Hospital of Pittsburgh, Hospital, PMS2, Genetics, Patient, Genetic testing, HD, Outline of counseling, Pharmaceutical industry, Nursing, Communications satellite, Medical imaging, Birth control, Vaccine, Woman, Invitae

SAN FRANCISCO, Oct. 10, 2023 /PRNewswire/ -- Researchers from Invitae (NYSE: NVTA), a leading medical genetics company, are showcasing their work next week at the National Society of Genetic Counselors (NSGC) 42nd Annual Conference in Chicago that highlights the importance of genetics-informed patient care. In addition to its research presentations, the company will present the Heart of Genetic Counseling Award which recognizes excellence in the field of genetic counseling.

Key Points: 
  • In addition to its research presentations, the company will present the Heart of Genetic Counseling Award which recognizes excellence in the field of genetic counseling.
  • "The NSGC Annual Conference is a great opportunity for Invitae researchers to share cutting-edge scientific advancements with genetic counselors who play an integral role in genetics-informed patient care," said Robert Nussbaum, M.D., chief medical officer at Invitae.
  • Invitae joins NSGC in presenting the Heart of Genetic Counseling Award – honoring excellence in genetic counseling and patient care as recognized by patients.
  • To learn more about Invitae's presence at the NSGC 42nd Annual Conference or the Heart of Genetic Counseling Award, visit our website .

Kidney Month: A Time of Unity and Action on Behalf of 37 Million Living with Kidney Disease

Retrieved on: 
Tuesday, February 28, 2023
Diabetes, Therapy, GSK, Dialysis, Disease, AKF, CSL Vifor, Janssen Pharmaceuticals, Patient, Kidney disease, Kidney, American Kidney Fund, Kirin-Amgen Inc v Hoechst Marion Roussel Ltd, AstraZeneca, Hypertension, End Stage Renal Disease Program, Nephrology, Novartis, Caregiver, Stroke, Kidney failure, Pharmaceutical industry

This March, AKF urges those in the kidney community and beyond to come together in support of all those affected by kidney disease.

Key Points: 
  • This March, AKF urges those in the kidney community and beyond to come together in support of all those affected by kidney disease.
  • A highlight of Kidney Month for the kidney community will be AKF’s Kidney Action Week , which will be held March 20-24.
  • Kidney Action Week will include a Congressional Briefing that will highlight the need to address prevention and management of diabetes and hypertension, the two leading causes of kidney failure.
  • In addition to kidney failure, kidney disease can lead to other health problems, including stroke or heart attack.

KIDNEY GROUP INVITES 2023 MEDAL OF EXCELLENCE NOMINATIONS

Retrieved on: 
Wednesday, November 9, 2022
Taiwan Excellence Awards, MSN, Criterion, Social work, White House, American Board of Internal Medicine, MS, Congress, CMS, Patient, Kidney failure, Association, End Stage Renal Disease Program, Dialysis, U.S. Department of Labor, Office of Inspector General, ESRD, FMLA, CNN, Royal Canadian Legion Cadet Medal of Excellence, USMC, Health education, American Association, Medal, Nephrology, Program, American Board of Commissioners for Foreign Missions, Immunodeficiency, FAAN, DO, Kidney transplantation, Internal medicine, COVID-19, RN, Policy, FASN, Doctor of Philosophy, Transplant surgeon, Master of Science, History, Family and Medical Leave Act of 1993, Transplant, Kidney, Advancing American Kidney Health, Social media, Research, Awareness, Risk, Office of Inspector General, U.S. Department of Health and Human Services, FACP, Pharmaceutical industry, Medicine, MD, Dietitian

WASHINGTON, Nov. 9, 2022 /PRNewswire/ -- The American Association of Kidney Patients (AAKP), the oldest and largest independent kidney patient organization in the U.S., has issued its call for nominations for its 2023 Medal of Excellence Award. The deadline for submissions is November 30, 2022. The AAKP Medal of Excellence Program elevates renal healthcare professionals in seven categories: Transplant Surgeon, Transplant Professional, Physician, Nurse, Social Worker, Dietitian, and Dialysis Technician.

Key Points: 
  • WASHINGTON, Nov. 9, 2022 /PRNewswire/ -- The American Association of Kidney Patients (AAKP), the oldest and largest independent kidney patient organization in the U.S., has issued its call for nominations for its 2023 Medal of Excellence Award.
  • The AAKP Medal of Excellence Program elevates renal healthcare professionals in seven categories: Transplant Surgeon, Transplant Professional, Physician, Nurse, Social Worker, Dietitian, and Dialysis Technician.
  • Paul T. Conway , Chair of AAKP's Policy and Global Affairs and a 42-year kidney patient, stated, "The Medal of Excellence program is an extension of our national strategy to redefine high-quality kidney care based on the standards and needs of kidney patient consumers.
  • About the American Association of Kidney Patients (AAKP): AAKP was founded in 1969 by six dialysis patients determined to extend life-saving kidney treatments to every American at risk of kidney failure.

Gates Biomanufacturing Facility Announces Manufacture of Recombinant Protein - Alzheimer's Disease Vaccine for Institute for Molecular Medicine's Clinical Trials

Retrieved on: 
Friday, November 4, 2022
Linda, Doctor of Philosophy, RNA, Neurodegeneration, DNA, Research, University of Colorado Hospital, Therapy, Hospital, University of Colorado School of Medicine, Institute, Biotechnology, Anschutz Medical Campus, Antibody, Alzheimer's disease, Human, FDA, Adult, Drug, Patient, Gates, University, Rapunzel's Tangled Adventure (season 2), A-DNA, Regenerative medicine, Program, Neuron, NIA, Private sector, National Institute, Pathology, GBF, Children's Hospital Colorado, Vaccine, Risk, Partnership, Molecular medicine, AD, Tauopathy, IMM, Disease, End Stage Renal Disease Program, BDS, GMP, Laboratory, Children's Hospital, Down syndrome, Pharmaceutical industry, Neurology

IMM selected GBF as its exclusive cGMP-grade BDS manufacturing partner supporting clinical supply for IMM's recombinant protein vaccines, including AV-1980R.

Key Points: 
  • IMM selected GBF as its exclusive cGMP-grade BDS manufacturing partner supporting clinical supply for IMM's recombinant protein vaccines, including AV-1980R.
  • As a result of this work, AV-1980R Drug Substance can be used for phase 1 and phase 2 clinical trials in humans.
  • Abnormal Tau aggregation into neurofibrillary tangles is the hallmark of different tauopathies - neurodegenerative disorders that include Alzheimer's Disease (AD).
  • The facility currently produces therapeutic biologics; recombinant protein, nano-particle conjugate, nucleic acid-based therapeutics as well as CAR-T cells and other cell therapy products for clinical trials.

End Stage Renal Disease Global Market Report 2022: Value to Reach $18.06 Billion by 2027 at a CAGR of 16.63% - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 7, 2022
Health, Infectious Diseases, Acquisition, Decision-making, USD, Treatment, Research, Strategic management, Peritoneal dialysis, Market share analysis, User (computing), Business Growth Fund, Value, Dialysis, Customer support, COVID-19, Growth, Collaborative partnership, Transplant, Investment, CAGR, Weakness, Hospital, Kidney, Diagnosis, Use, End Stage Renal Disease Program, Clifton Springs Hospital & Clinic, Royal Belfast Academical Institution, News, Compound annual growth rate, Kidney bean, State, Gaps, Mergers and acquisitions, Medical device, Retail, Blood, Hemodialysis

The "End Stage Renal Disease Market Research Report by Treatment (Dialysis and Transplantation), Diagnosis, End-User, State - United States Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "End Stage Renal Disease Market Research Report by Treatment (Dialysis and Transplantation), Diagnosis, End-User, State - United States Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
  • The United States End Stage Renal Disease Market size was estimated at USD 7,173.99 million in 2021, USD 8,638.02 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 16.63% to reach USD 18,063.62 million by 2027.
  • This research report categorizes the End Stage Renal Disease to forecast the revenues and analyze the trends in each of the following sub-markets:
    Based on Treatment, the market was studied across Dialysis and Transplantation.
  • Based on Diagnosis, the market was studied across Blood tests, Imaging tests, Kidney sample removal for testing, and Urine tests.

Insights on the Dialyzer Global Market to 2027 - by Type, Usage Type, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Friday, May 13, 2022
Medical Devices, Health, National Association Medical Staff Services, Poisoning, Diabetes, Medical tourism, Efficiency, Industry, Dialysis, Blood, End Stage Renal Disease Program, ESRD, Prevalence, Degenerative disease, Growth, COVID-19, Hypertension, Transplant, Pharmaceutical industry, Potash

This, along with the growing geriatric population around the world, represents one of the key factors driving the market.

Key Points: 
  • This, along with the growing geriatric population around the world, represents one of the key factors driving the market.
  • How has the global dialyzer market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global dialyzer market?
  • What is the structure of the global dialyzer market and who are the key players?

Global End-Stage Renal Disease (ESRD) Market to 2032 - Insight, Epidemiology and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 6, 2022
Health, Pharmaceutical, Organizing, Competition, ESRD, Diagnosis, End Stage Renal Disease Program, Lists of people executed in the United States, Research, PESTLE, SWOT, Chronic kidney disease, Epidemiology, Report, SME, Porter's five forces analysis, Awareness, Growth–share matrix, Disease, Pharmaceutical industry

The "End-Stage Renal Disease (ESRD) - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "End-Stage Renal Disease (ESRD) - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's offering.
  • This report delivers an in-depth understanding of the End-Stage Renal Disease (ESRD), historical and forecasted epidemiology as well as the End-Stage Renal Disease (ESRD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The End-Stage Renal Disease (ESRD) market report provides current treatment practices, emerging drugs, End-Stage Renal Disease (ESRD) market share of the individual therapies, current and forecasted End-Stage Renal Disease (ESRD) market Size from 2019 to 2032 segmented by seven major markets.
  • Their opinion helps to understand and validate current and emerging therapies treatment patterns or End-Stage Renal Disease (ESRD) market trend.

Worldwide Chronic Kidney Disease Industry to 2026 - North America is Expected to Hold the Largest Market Share - ResearchAndMarkets.com

Retrieved on: 
Friday, January 7, 2022
Health, Pharmaceutical, Janssen Pharmaceuticals, Blood, National Kidney Foundation, International Society, Food, Chronic kidney disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Kidney, SGLT2, Glomerular filtration rate, Growth, Therapy, Man, Patient, ISN, Cancer, Prevalence, Death, End Stage Renal Disease Program, Kidney disease, List of international sports federations, Disease, Kidney cancer, International Society of Nephrology, CKD, Type 2 diabetes, Creatinine, FDA, Woman, Boehringer Ingelheim, Canadian International Council, Diagnosis, ESRD, Eli Lilly, Risk, Incidence, Canagliflozin, EGFR, American Cancer Society, International Journal of Nephrology and Renovascular Disease, Pharmaceutical industry, Nephrology

The glomerular filtration rate (eGFR) is calculated to evaluate u milliliters of waste the kidney is able to filter in a minute.

Key Points: 
  • The glomerular filtration rate (eGFR) is calculated to evaluate u milliliters of waste the kidney is able to filter in a minute.
  • Hence, owing to the rising prevalence of chronic kidney diseases the market is expected to witness high growth over the forecast period.
  • North America held the largest market share in previous years and is anticipated to do the same in the forecast period.
  • Thus, the presence of these market propelling factors in this region is anticipated to offer lucrative growth to the market.

Full FDA Approval Of Pfizer/BioNTech COVID-19 Vaccine

Retrieved on: 
Monday, August 23, 2021
End Stage Renal Disease Program, White House, Friends, Acute kidney injury, COVID-19, Life expectancy, Transplant, Congress, Twitter, COVID-19 vaccine, Program, Life, ESRD, Dialysis, CMS, Dream, Conditional sentence, Policy, Social media, Food, Disease, Kidney, Health, Death, American Association, Advancing American Kidney Health, Immunodeficiency, EUA, Pfizer, FMLA, U.S. Department of Defense Strategy for Operating in Cyberspace, Kidney failure, Safety, Risk, Patient, AKI, Vaccine, U.S. Department of Labor, Office of Inspector General, Family and Medical Leave Act of 1993, Association, FDA, Facebook, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry

The Pfizer/BioNTech vaccine, and two otherCOVID-19 vaccines, have been available over the course of the past year under FDA's emergency use authorization (EUA).

Key Points: 
  • The Pfizer/BioNTech vaccine, and two otherCOVID-19 vaccines, have been available over the course of the past year under FDA's emergency use authorization (EUA).
  • Just as importantly, unvaccinated Americans pose an extremely serious risk to their families, friends, and communities; especially to people whose unique vulnerabilities to COVID-19 infection are not visible.
  • These people include immunosuppressed kidneytransplant recipients and immunocompromised patients managing severe chronic diseases and other medical conditions.
  • Follow AAKP on social media at @kidneypatient on Facebook and @kidneypatients on Twitter and visit our website at https://aakp.org/ .